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High-density lipoprotein (HDL) is an endogenous biological molecule with high 
heterogeneity, playing critical roles in several biological events including anti-
inflammation and lipid homeostasis. However, it is difficult to uncover the detailed 
structural and biological function of each HDL component, mainly due to the heterogeneity 
of HDL induced by multiple compositions and HDL-associated proteins. To overcome 
heterogeneous characteristics of HDL, reconstituted HDL (rHDL) form has been presented 
to synthesize simplified form of HDL with major components in HDL, such as 
apolipoprotein A1 (apoA1), phospholipids (PL), and free cholesterol (FC). Recent 
developments in microfluidics have allowed us to produce more homogeneous HDL-
mimetic nanoparticles with higher reproducibility. In addition, computational approaches 
have been introduced to conduct structural analysis of nanoparticles along with the 
development of computational methods.  
we introduce a computational strategy of molecular dynamic (MD) simulation with 
experimental correlations. Coarse grained (CG) MD simulation enables the detailed 
prediction of the HDL-mimetic nanoparticle’s structure, and binding structure of HDL with 
a major HDL associated proteins (HAPs), paraoxonase1 (PON1), while the microfluidic 
platform leads compositionally homogeneous nanoparticle synthesis to validate 
computational results. Our approach provides an insight to precisely analyze the 
compositionally and functionally heterogenous HDL and can be applied to elucidate the 
detailed binding mechanism of other associated proteins on well-defined HDL. 
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CHAPTER 1. INTRODUCTION 
1.1 Background 
1.1.1 High-density lipoprotein 
High-density lipoprotein (HDL) is a natural multifunctional nanoparticle that plays 
important roles in terms that it has been known to transport cholesterol lipids from 
peripheral tissues to the liver, which is called reverse cholesterol transport (RCT) [2-4]. 
HDL is nano-sized particle that exists in various forms (discoidal and spherical) regarding 
its heterogeneous compositions [5-8]. Apolipoprotein A1 (apoA1, 243 amino acids) [9], 
major protein in HDL, is secreted ma inly from the liver in the lipid-poor or lipid-free form. 
And the apoA1 becomes lipid-bound state by uptake of free cholesterols and phospholipids 
from plasma membrane mediated by ATP-binding cassette (ABC) transporter A1 (ABCA1) 
[10, 11], resulting in the formation of discoidal shape (nascent HDL) [12]. These discoidal 
particles are composed of phospholipids bilayer with amphiphilic cholesterol and apoA1s 
encircle outer perimeter of lipids with double-belt like conformation [13-15]. After lecithin 
cholesterol acyltransferase (LCAT) esterifies cholesterol in lipid bilayer [16, 17], 
cholesteryl esters (CEs) move from the lipid bilayer surface to the hydrophobic core of 
HDL, transforming discoidal shape to spherical conformation. Also, HDLs undergo 
dynamic compositional changes by interacting with lipid transfer proteins, such as 
cholesteryl ester transfer protein (CETP) and phospholipid transfer protein (PLTP), 
becoming large size sphere [18]. Then, HDLs transport CEs to the liver mediated by 
scavenger receptor B1 (SR-B1), which selectively takes up lipids[19-21]. During this 
dynamic remodeling of HDLs, an imbalance between the amphipathic surface and 
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hydrophobic core may be possible reason that HDL size becomes large with three to four 
apoA1 molecules [22]. 
1.1.2 Heterogeneous property of HDL 
One important reason to study HDL is because HDL has long been believed to be a 
therapeutic promise [23] due to the fact that plasma HDL levels have inverse association 
with cardiovascular disease (CVD), which is top cause of death in U.S. [24, 25]. However, 
in recent clinical studies, raising plasma HDL levels failed to demonstrate reduced CVD 
events in patients with coronary artery disease (CAD) [26], possibly due to dysfunctional 
HDL nanoparticles that no longer have the long-believed atheroprotective function [27]. In 
fact, it has been demonstrated that HDL components are dynamically modified during a 
number of biological processes, generating a heterogeneous population of HDL and 
inducing altered endothelial effects of HDL. For example, paraoxonase-1 (PON1), an 
enzyme of HDL, contributes to the anti-atherogenic function of HDL [28-31] whereas 
HDL-bound serum amyloid A (SAA) becomes pro-inflammatory [32-35]. Due to the 
overwhelming number of HDL components, however, the mechanisms of the altered 
effects remain poorly understood [36, 37]. 
1.1.3 Reconstituted HDL 
Despite of heterogeneous characteristic of HDL, most current studies inevitably rely on 
bare measurement of in vivo plasma level of HDL and associated proteins. The 
heterogeneous properties of which result in high variations and low reproducibility 
restricting mechanistic studies on HDL functions. To overcome these challenges, 
reconstituted HDL (rHDL) has been developed to study the structural and biological 
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functions of HDL [38-41]. We showed a microfluidic synthesis technology that allowed us 
to enhance HDL synthesis reproducibility and particle homogeneity [42, 43], and were 
recently able to detect the distinct biological function and drug delivery performance of 
two different engineered HDL-mimetic nanoparticles (eHNPs) in vitro and in vivo [44]. 
This integrated approach has provided a better understanding of the biological roles of 
apolipoprotein A1 (apoA1), the scaffold protein of HDL that has important biological roles 
[45-48],  and the mimetic peptide r4F in a mechanistic manner, with potential to investigate 
the biological roles of a variety of HDL functional components. However, it would be 
inefficient to experimentally study the functions of a number of HDL components and it 
remains unclear how these elements interact with HDL for the specific biological functions 
1.1.4 Molecular dynamics simulation on HDL 
Meanwhile, computational approaches using molecular dynamics (MD) simulations have 
been applied for a better fundamental understanding of structural dynamics of HDL [49]. 
The scaffold protein, apoA1, of discoidal HDL has been comprehensively investigated 
Figure	1.	reconstitute	HDL	with	major	components	of	HDL	(two	apoA1s	and	DMPCs)	
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using MD simulations over the last two decades. Applying theoretically and experimentally 
proposed apoA1 structures, such as double-belt, picket fence, and hairpin model, on MD 
computations, the most stable (low potential energy comparing to others) apoA1 structure, 
double-belt model, has been proposed among them. Then, this double-belt conformation 
of apoA1 has been widely accepted for discoidal HDL [50-55]. Efficient coarse-grained 
(CG) forcefield [56, 57] has successfully simulated the disassembly and morphological 
transition (discoidal to spherical) of rHDL [58-60]. While there have been extensive studies 
of structural analysis of discoidal HDL, much less is known about the apoA1 structure in 
spherical HDLs. They contain CEs and triglycerides in hydrophobic core, encapsulated by 
amphipathic phospholipids and cholesterol surface. Despite of a few published reports 
regarding spherical HDL experimentally, trefoil apoA1 model has been proposed with 
cross-linking chemistry with mass spectrometry (MS) [48]. However, this topic is still 
understudied. In addition, even though there have been comprehensive studies of structural 
and biological functions of HDL, little is known about the relations between HDL and its 
associated elements responsible for HDL functions. For example, paraoxonase-1 (PON1) 
promotes cholesterol efflux and inhibits low-density lipoprotein (LDL) oxidation [61, 62]. 
However, it remains unclear how PON1 interacts with HDL and how the interactions alter 
the biological functions of HDL.  
1.2 Molecular dynamics simulation 
Since 1970s, MD simulations have applied to biological system, solving equation of 
motion for the atoms. The results provided diffusive characteristics of atom motions [63]. 
Since then, MD simulation approach to biological studies has grown rapidly, as 
development of MD simulation code itself along with the rising performance of computer 
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hardware. The exponential increase of manuscripts related to MD simulation is clear as 
searching the number of publications with the keywords, “molecular dynamics” [1]. This 
trend shows clear importance of MD simulation for predicting the function of molecules, 
and discovering the mechanisms underlying functions depending on a complete 
understanding of biological molecules, including their dynamics. 
	 	
1.2.1 Basic knowledge of MD simulation 
MD simulation calculates Newton’s second law of motion numerically to determine the 
trajectory of atoms and molecules. 




, where F is force on an atom, m is mass of the atom, and a is the acceleration of atom. 
And F(r) can be expressed by potential energy function regarding coordinates of all 
atoms, U(r). 
𝑭(𝒓) = −𝜵𝑼(𝒓) 	 	 	 	 (	2	)	
Then,  
𝒅𝒗 𝒅𝒕⁄ = 	𝑭(𝒓) 𝒎⁄ 	 	 	 	 	 (	3	) 
𝒅𝒓 𝒅𝒕⁄ = 𝒗	 	 	 	 	 	 (	4	)	
	
Those two derivatives are solved by numerical integrations. And Potential energy U(r) is 
combined with bonded interactions (bonds, bend angles, torsion angles) and non-bonded 
interaction (Lennard-Jones: van der Waals, Coulomb: electrostatic).  
𝑼(𝒓) = 𝑼𝒃𝒐𝒏𝒅𝒔 + 𝑼𝒃𝒆𝒏𝒅	𝒂𝒏𝒈𝒍𝒆𝒔 + 𝑼𝒕𝒐𝒓𝒔𝒊𝒐𝒏	𝒂𝒏𝒈𝒍𝒆𝒔 + 𝑼𝑳𝑱 + 𝑼𝑪𝒐𝒖𝒍𝒐𝒎𝒃		 	 (	5	) 
1.2.1.1 Non-bonded interactions 
Force fields divide non-bonded potential into two Van der Waals and electrostatic 
interactions. 
 
Lennard-Jones (LJ) potential (Van der Waals): 
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𝑼𝑳𝑱(𝒓) = 𝟒𝜺[(𝝈 𝒓⁄ )𝟏𝟐 − (𝝈 𝒓⁄ )𝟔]	 	 	 	 (	6	)	
𝜀 indicates the strength of the interaction and 𝜎 is a length scale. Both parameters are 
chosen regarding particular properties of the system. LJ potential shows strong repulsive 




: repulsive term) due to overlapping electron orbitals. On 
the other hand, attraction force is the maximum when r ≈1.122	𝜎. 
 
Coulomb potential (electrostatic): 















Comparing to the molecule distance, r in LJ potential, Coulomb potential is less sensitive 
in the distance, and it indicates very long-range potential comparing to LJ potential. 
 
1.2.2 MD simulation flow chart 
General MD simulation flow is shown in above figure. Basically, a molecule structure, that 
we want to simulate, is mandatory for sure. And we need specific force fields regarding 
Figure	4.	General	molecular	dynamics	simulation	flow	chart 
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what we want to solve. Then a simulation topology file can be generated in GROMACS. 
The most important thing to consider in entire simulation process is to set up the simulation 
box size. Large size simulation box contains many molecules such as water and ions, then 
simulation time will rise exponentially. Molecule fitted box size may arise a problem. 
Because each box faces are set as periodic boundary condition, the molecule sometimes 
cross a box face, interacting with other side of the molecule. So, it is critical to set up the 
optimal size of simulation box. In the box, designated molecules, water molecules, and 
ions are located. Before the actual simulation, the structures in the system should be relaxed 
through the process called energy minimization. Then, equilibration of solvent and ions 
around molecule structure is needed to set designated temperature and pressure, and to 
avoid system collision. After two equilibration processes, it is ready to implement MD 
simulation. After this whole process, several resulting files are generated and those are 
used for further analysis.  
 
1.2.3 Coarse-grained model (MARTINI force field) 
Coarse-grained (CG) MD simulation model has been developed to analyze the dynamics 
of large size molecules. Although it is inevitably true that CG MD simulation loses its 
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accuracy comparing to all atom (AA) model by modeling 4 atoms into 1 big bead (four-to-
one mapping), it enlarges time and length scale of the system. Currently, CG MD 
simulation is used to predict the tertiary structure, maintaining secondary structure, which 
is one limitation to be solved as a future research. As each force field has their own purpose 
to calculate, MARTINI force field is specialized to compute the interaction between lipid 





1.2.4 Software packages 
There are several MD simulation open source codes. They have their own particular force 
fields to solve molecular interaction, which is the reason to simulate. Remarkably, the use 
of GROMACS and LAMMPS are growing exponentially, although the Figure 6 does not 
show clear explanations because many publications do not cite software. Visual molecular 
dynamics (VMD) is tool to visualize and analyse resulting molecule structures. These 
increasing number of citations of computational approaches to biological system 





GROMACS stands for GROningen Machine for Chemical Simulation, developed in the 
Biophysical Chemistry of university of Groningen. The algorithm that they adopt enables 
faster simulation time than many simulation programs. And it is supported by different 
force fields, which makes GROMACS very flexible. Besides, MARTINI force field is 
compatible to GROMACS. 
 
In my research, I adopt GROMACS molecular dynamics package with advantages in terms 
of simulation speed, flexibility, extensive amount of information on the web (forum), and 
well-documented information in manual. And MARTINI force field is used for CG MD 
simulation, because it is specialized to conduct cell membrane and protein simulations 
which are related to my research. And it has a number of publications in high impact journal 
indicating its reliability. VMD is used as a molecular visualization program. It allows us to 
display, animating, and even analyzing biomolecular systems with 3-dimensional graphics.  
1.3 Research objectives 
The primary objective of our study is to expand our understanding in HDL-mimetic 
nanoparticle modeling with the CG MD simulation with experimental correlations. We 
chose to specifically study engineered HDL-mimetic nanoparticles (eHNPs), and one of 
HDL associated protein, paraoxonase-1 (PON1) to predict protein binding structure to 
eHNP. To achieve our primary objective, the study is divided into the following aims: 
1. Apply a coarse-grained molecular dynamics simulation approach to model the 
structure of apolipoprotein A1 based HDL-mimetic nanoparticles (eHNP-A1). 
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2. Apply a coarse-grained molecular dynamics simulation approach to model the 
structure of r4F peptide-based HDL-mimetic nanoparticles (eHNP-r4F) with direct 
comparison to eHNP-A1 
3. Investigate preferable PON1 binding structure to eHNPs and its binding mechanism  
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CHAPTER 2. COMPUTATIONAL MODELING OF 
APOLIPOPROTEIN A1 BASED HDL-MIMETIC 
NANOPARTICLE FOR STRUCTURAL ANALYSIS 
2.1 Background 
2.1.1 Double-belt structure of apoA1 in nascent HDL 
As CG MD simulation codes have been developed along with the performance of computer 
processors, it enables large size and complex molecules analysis faster than conventional 
AA model. This computational approach has been used to investigate HDL nanoparticle 
structure in biological system. To avoid compositional complexity of HDL, nanoparticles 
have been designed to simplified form, named nanodiscs with major components in HDL, 
apoA1 and phospholipids. Initial nanodisc model has 1:80 molar ratio (apoA1: DMPC), 
because experimentally well-known structure has the ratio at earlier time when nanodisc 
researches were initiated [64, 65]. And initial studies were of interest in apoA1 structure in 
HDL, due to the biologically functional importance of apoA1 in HDL, and apoA1 structure 
is still not clearly uncovered. However, apoA1 structure in nascent HDL has been 
extensively studied computationally, suggesting that HDL with double-belt like apoA1 
showed stable energy status among other proposed models, such as picket fence and hairpin 
model. Besides, shape transition from discoidal to spheroidal HDL has been studied by 
incorporating 60 mole of hydrophobic cholesteryl ester (CE) molecules without any 
structural change in apoA1 [58]. This provided possible CE molecules incorporating 
mechanism, showing shape transition.  
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2.1.2 Trefoil model of apoA1 in spherical HDL 
 
While the apoA1 structure in discoidal HDL has been comprehensively explored, much 
less is studied about the apoA1 structure in spherical HDL [48, 66, 67]. Spherical HDL 
contains triglyceride and CE molecules in the hydrophobic core, and those hydrophobic 
molecules are surrounded by amphipathic phospholipid and cholesterol monolayer. The 
reason why the apoA1 structure in spherical HDL is important is that the activity of HDL 
remodeling factors such as LCAT [45] and CETP [68] might be affected by HDL 
nanoparticle shape. Trefoil apoA1 model was first proposed by cross-linking chemistry 
with mass spectrometry (MS). Both discoidal and spherical HDL show similarity in general 
structural organization of apoA1, and cross-linking pattern was explained in human plasma 
HDL. However, few publications have experimentally demonstrated spherical HDL, and 
computational approach has never been applied for this model.  
 
Here, I reproduce double-belt apoA1 configured HDL-mimetic nanoparticle with 
experimental correlation to confirm validity of CG MD simulation model, which is critical 
step for computational reliability. Then, I investigate both double-belt and trefoil apoA1 





2.2.1 Modeling engineered HDL-mimetic nanoparticles with different ratio 
CG MD simulation was performed to reproduce and explore the structure of rHDL. 
MARTINI force field [56] was used as CG model, because it is well-known for cell 
membrane and protein simulation with a number of publications. First, three discoidal 
rHDL models have been simulated to prove the structural differences and energy status. 
They have different apoA1 and DMPC ratio, which are 1:60, 1:80, and 1:100. Those ratios 
were selected within the range of nascent discoidal HDL from blood plasma [6]. Initially, 
Figure	7.	Energy	and	structural	comparison	among	three	different	ratios	
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lipid bilayer and apoA1 double-belt model was used to reduce the simulation time, 
assuming final structure as disc type nanoparticle. This is because many studies about final 
structure of nanodiscs have been discusses. Those simulations were to validate simulation 
setup with the results from robust microfluidic nanoparticle synthesis. And 1:80 
composition is the ratio that has been widely used in nanodiscs research, because this ratio 
was well documented from experiment at that time when nanodiscs research was initiated 
[64, 65]. I set up this simulation conditions based on the past report [69], which is lastest 
publication of CG MD simulation with MARTINI force field. I implemented simulation 
for 1000 ns which was enough, as other researches did for 500 ns. Over the simulation 
time, three nanodiscs with different composition kept their structures, and apoA1 structure 
maintained double-belt shape, as we expected. Among them, 1:60 ratio shows the lowest 
potential energy, which indicates stability of nanodiac. 1:100 ratio is still structurally 
stable, but relatively less stable than 1:60 case. This makes sense, because the distance 
among molecules are too short which has repulsion force, as demonstrated in LJ potential 
graph. As well as potential energy, root mean square deviation (RMSD) is another factor 
to explain the stability of molecule structure. RMSD of apoA1 for three simulations shows 
no significant differences, which means apoA1 structure stably encircled DMPC bilayer. 
In addition, due to the marginal location of double-belted-apoA1s, the radius of apoA1-
ring gradually increased as the composition changed from 1:60 to 1:80, and saturated at 
1:100 composition, suggesting that the size of HDL nanoparticle is confined by the 




2.2.2 Computational model validation with experimental correlation 
To evaluate our simulation model by comparison with experimental results, we 
implemented our microfluidic technology to synthesize well-defined and highly 
homogenous HDL-mimetic nanoparticle comprising apoA1 and DMPC (engineered HDL-
mimetic nanoparticle-A1; eHNP-A1), which led a composition of 1:73 mole ratio of apoA1 
to DMPC [44]. The synthesized eHNP-A1 was highly homogenous shown in size 
distribution in dynamic light scattering (DLS), and well correlated with our simulation 
model as well as physiological pre-beta HDL as shown in transmission electron 
microscopy (TEM), possessing a discoidal shape with a 10 nm of diameter. The correlation 
of our simulation model with the microfluidically synthesized eHNP-A1 confirms the 




2.2.3 Shape transition and loading capacity 
Although previous research showed shape transition from discoidal nanodiscs, only 60 
number of CE molecules were added in the simulation system to see maturation of HDL. 
However, matured HDL from blood plasma contains more hydrophobic lipids, such as 
triglycerides and CEs in the core of HDL. So, it is important to know (1) how many 
hydrophobic molecules can be incorporated in double-belt configured discoidal nanodiscs, 
also (2) if structural change affects the structure of double-belt apoA1. To explore shape 
transition of nanoparticle, the number of CE molecules have been gradually added to 
discoidal eHNP-A1 in the system. As previous report has showed [shih], discoidal eHNP-
A1 transformed to spheroidal shape until adding 60 CE molecules. Until adding 120 CE 
Figure	9.	Shape	transition	from	discoidal	to	spherical	by	incorporating	CE	molecules 
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molecules, eHNP-A1 incorporated with them, transforming to spherical shape. However, 
240CE molecules were not completely inside of eHNP-A1. 46 CE molecules were found 
outside of eHNP-A1, aggregating each other. Total 194CE molecules can be incorporated 
in 1:80 discoidal eHNP-A1. In addition, radial distribution function (RDF) analysis 
demonstrated no significant size changes while transforming the shape. It proposes double-
belt apoA1 structure maintains initial 1:80 discoidal eHNP-A1 size. Additionally, apoA1 
double-belt structure was not affected by simply adding hydrophobic molecules.  
 
2.2.4 apoA1 structural analysis of trefoil in spherical HDL 
Generally, it is impossible to form discoidal shape with trefoil apoA1 configuration. So, 
initially, 90 CE molecules were added into the nanoparticle which has already been 
Figure	10.	Diameter	comparison	among	different	CE	contained	nanoparticles 
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modeled with 1:80 discoidal eHNP-A1 and replaced from double-belt to trefoil apoA1 to 
explore apoA1 structural change from trefoil form. Like previous double-belt case, the 
number of CE molecules were gradually increased in the system. With trefoil apoA1 
configuration, 330 CE molecules were found inside of hydrophobic core of eHNP-A1, 
while 30 CE molecules were aggregated outside and were not involved in the nanoparticle. 
Comparing to double-belt eHNP-A1 case, trefoil structured eHNP-A1 can contains more 
hydrophobic molecules inside of nanoparticle, as maximum 330 CE molecules. This result 
supports the existence of larger size HDL in blood plasma with 3-5 molecules of apoA1. 






I successfully applied CG MD simulation and reproduced discoidal shaped HDL-mimetic 
nanoparticles, as well as validating with experimental correlations. As well as this, I was 
able to model and synthesize physiologically relevant to human plasma HDL. This 
validated MD simulation configuration has been applied to uncover currently unsolved 
biological questions regarding HDL structure. From these simulations, we have come to 
know the structural roles of apoA1. Both double belt and trefoil apoA1 models limit the 
size of nanoparticles, stabilizing the form of nanoparticles. Also, the increase in the size 
with three apoA1 molecules may explain the large size HDL existence with 3-5 number of 





2.4.1 MD simulation 
GROMACS 4.5.7 [70] was used as MD simulation software package with MARTINI force 
field [56] in conjunction with ElNeDyn[57]  to maintain secondary and tertiary structure. 
Double-belt apoA1 structure was obtained from CHARMM-GUI [71, 72]. DMPC 
molecules were used as phospholipid. For 3 simulation cases, 120, 160, and 200 number 
of DMPC bilayer molecules were located inside of double belt apoA1 in 15 x 15 x 15 x nm 
sized simulation box, as an initial configuration. The system was solvated with water 
molecules and neutralized with Na+ counterions. Then, this system was energy minimized 
with steepest descent algorithm for 5000 steps. Next, equilibrium step was performed with 
molecule restraints. Simulation time step, 20 fs was set up, which is proper range in 
MARTINI force field. Total simulation time, 1000 ns was set for all simulations. 
Temperature kept 298K for RT.  
 
2.4.2 eHNP synthesis 
A three-inlet microfluidic device that generates propagating microvertices was used for a 
single-step self-assembly of eHNP-A1 according to the previous report with slight 
modification [44]. In brief, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti 
Polar Lipids, AL; 2.75 mg/mL) in absolute ethanol was introduced into the center inlet of 
the microfluidic device at a flow rate of 0.8 mL/min. Apolipoprotein A1 (Millipore Sigma, 
MA; 0.2 mg/mL) in phosphate buffered saline (PBS, pH = 7.4) was introduced into two 
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outer inlets at a flow rate of 2.2 mL/min. Each of DMPC and apoA1 solution was 
homogenously injected using a programmable syringe pump (Harvard Apparatus, MA) at 
the desired flow rates. After running the syringe pump, the mixture solution was collected 
from outlet, followed by transferring the solution to centrifugal membrane filter (EMD 
Millipore, Germany) with a molecular weight cut off (MWCO) of 50,000, and purified 5 
times in PBS at a speed of 3900 rpm for 30 min. Synthesized eHNP-A1 was stored at 4oC 
for further modification.  
 
2.4.3 eHNP characterization 
Hydrodynamic volume of eHNP-A1 was obtained by a Zetasizer Nano (Malvern 
Instrument, Malvern, UK). For the monitoring of size and morphology of eHNP-A1, 
negatively stained samples were observed using a transmission electron microscope (TEM; 
Hitachi 7700, Hitachi, Japan) at 120kV coupled with the Digital Micrograph camera and 
software suite from Gatan. 
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CHAPTER 3. COMPUTATIONAL MODELING OF R4F 
PEPTIDE BASED HDL-MIMETIC NANOPARTICLE WITH 
DIRECT COMPARISON TO APOA1 BASED HDL-MIMETIC 
NANOPARTICLE 
3.1 Background 
3.1.1 HDL mimetic nanoparticles with apoA1-mimetic peptides 
Along with the engineering HDL-mimetic nanoparticles with precursors from blood 
plasma, various apoA1-mimetic peptides for synthetic form of HDL has been developed to 
target diseases, such as CVD and Alzheimer’s disease (AD) [73, 74]. ApoA1 has 243 
amino acids, and it is composed of 10 alpha helices. Comparing to apoA1 structure, apoA1-
mimetic peptide are 18-22 amino acids with alpha helix structure. The main reason for use 
of apoA1-mimetic peptides is the cost. Comparing to apoA1, apoA1-mimetic peptides are 
cost-effective, and it does not need any purification and expensive tests to check infection 
and endotoxin free [75]. Among the studies regarding mimetic peptides, reverse-4F (r4F) 
has demonstrated the performance of drug delivery and atheroprotective role in mouse 
model [74, 76-79]. Engineered HDL-mimetic nanoparticle with r4F peptides has already 
shown HDL-like structure and biological relation to receptor B1, comparing to HDL. 
However, a direct comparison between r4F and apoA1 in HDL-mimetic nanoparticle 
(eHNP-r4F and eHNP-A1, respectively) form has never been studied. In this study, we 
apply combined approach to compare and analyze the structures between apoA1 and r4F 
in an HDL-mimetic nanoparticle, computationally and experimentally.    
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3.1.2 Structural difference between apoA1 and r4F peptide 
Figure	13.	Structural	differences	between	apoA1	and	r4F	peptide	
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 apoA1 is a major protein component of HDL in human blood plasma, which is composed 
of 243 amino acids and 10 alpha helices. apoA1 stabilizes lipid membrane on the surface 
of an HDL particle, and is related to anti-inflammatory function of HDL. Comparing to 
apoA1, r4F peptide has 18 amino acids, which is much shorter than apoA1. And amino 
acid arrangement is designed on purpose that hydrophobic residues are located in one side 
of the helix. The purpose of this design is to cover hydrophobic tail of membrane lipids.  
 
3.2 Results 
3.2.1 HDL-mimetic nanoparticles comparison from microfluidic synthesis  
We synthesized two types of HDL-mimetic nanoparticles with well-defined microfluidic 
synthesis platform. Resulting nanoparticles were physiologically relevant to nascent HDL, 
which are discoidal shape and closer to 10 nm. Both TEM images of eHNP-A1 and eHNP-
r4F showed famous rouleaux shape (like stacks of coins), indicating discoidal shaped 
nanoparticle. And the average size of eHNP-A1 is 10.1 nm and eHNP-r4F is 11.7 nm. 
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both nanoparticles are almost similar in size and homogeneity. In addition, both had an 
almost identical protein-lipid composition. However, morphological difference was 
observed 7 days after particle synthesis. While eHNP-A1 kept their size and homogeneity, 
eHNP-r4F showed particle aggregation. This comparison explained the stability difference 
between both nanoparticles, and eHNP-r4F stability lower than eHNP-A1 particles. We 
hypothesized that r4F peptide could not cover hydrophobic tail of DMPC, then the 
hydrophobic region exposed to the hydrophilic solvent tried to find the hydrophobic region 
in other nanoparticles. Finally, eHNP-r4F particle aggregated over time. 
 
3.2.2 Computational analysis of eHNP-r4F structure with CG MD simulation 
CG MD simulations have been performed for structural analyses of both eHNP-A1 and 
eHNP-r4F. MD simulation enabled 1 to 1 nanoparticle comparison in molecular level. Not 
like eHNP-A1 simulation, eHNP-r4F simulation took a long time, because there was no 
assumption regarding final structures. Initially, total 1020 molecules (r4F: 60, DMPC: 960, 
[reference]) were located in 30 nm x 30 nm x 30 nm simulation box. Then, water and ions 
were filled in empty space in the box. This simulation went through 3.5 μs until small 
eHNP-r4F nanoparticles became one big particle after aggregation. For 1 to 1 comparison, 
eHNP-r4F which had similar size to eHNP-A1 was chosen. There was significant structural 
difference which may explain the low stability of eHNP-r4F. In both eHNPs, DMPC lipids 
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formed bilayer as expected. However, apoA1 played a membrane scaffolding role in 
nanoparticle structure, covering hydrophobic tail of DMPC, which would prevent particle 
aggregation with adjacent nanoparticles. On the other hand, hydrophobic region of DMPC 
in eHNP-r4F structure was exposed to hydrophilic solvent, which has possibilities to 
aggregate with other nanoparticles because of hydrophobicity. Consequently, r4F peptide 
formation in eHNP-r4F reduces particle stability having more chances to aggregate.    
Figure	15.	Structural	comparison	between	eHNP-A1	and	eHNP-A1	from	MD	simulation	results	
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The view of entire simulation box would help to understand how eHNP-r4F is developing 
to one huge big particle. In initial configuration at 0 μs, each molecule was randomly 
distributed without any prediction of final structure. At 0.5 μs, 6 individual eHNP-r4Fs 
were seen, and r4F peptides were aggregated each other. Even, 3 particles in right hand 
side of simulation box, attached each other. Due to r4F peptides aggregation, hydrophobic 
tail of DMPC were opened to hydrophilic solvent, which led particle aggregation. Finally, 
several eHNP-r4Fs became one big particle. Even, some hydrophobic tail regions of 
DMPC were still exposed to water molecules, due to the lack of the number of r4F.   
3.2.3 Structural differences of eHNP-r4F regarding different mole ratios 
Figure	16.	Nanoparticle	aggregation	over	time	
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Main difficulty in eHNP-r4F synthesis is to cover whole hydrophobic tail of DMPC with 
r4F peptides, completely, as apoA1s do in HDL. One thing I could suggest with MD 
simulation was to increase the number of r4F peptide molecules to increase the possibilities 
to cover hydrophobic region, which would help to avoid particle aggregation. Three 
simulations were planned to suggest the best ratio to avoid aggregation by comparing each 
other (1:16, 1:8, 1:3, r4F: DMPC). From the results, although r4F peptide aggregation was 
inevitable, increasing the number of r4F peptide molecule helps to cover hydrophobic tail 
of DMPC, which may lead particle aggregation.   
 
3.3 Conclusion 
We implemented direct comparison between eHNP-A1 and eHNP-r4F to explore the 
structural role of membrane protein and peptides in HDL form. Microfluidic synthesis 
platform successfully provided both eHNP-A1 and eHNP-r4F nanoparticles which have 
Figure	17.	Structural	differences	regarding	the	mole	ratio	of	r4F	peptide	to	DMPC	
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similar morphology in shape, size, and composition. The only difference was 
nanoparticle’s stability that particle aggregation has been observed in eHNP-r4F after 7 
days from particle synthesis. MD simulation has been performed to demonstrate the 
stability of nanoparticles by showing structural differences. Simulation results have shown 
distinct differences of the structure between eHNP-A1 and eHNP-r4F. While apoA1 
completely encompassed DMPC bilayer forming eHNP-A1, r4F peptides did not encircle 
DMPC bilayer, aggregating each other. This led the exposure of hydrophobic tail of 
DMPC, in water, and this caused nanoparticle aggregation. Increasing the ratio of r4F to 
DMPC may help r4F peptides to rise the chance to cover hydrophobic region of lipid, 
avoiding lipid molecule aggregation.  
 
3.4 Methods 
3.4.1 MD simulation 
The MD simulations were performed using the GROMACS software package [70]. The 
coarse-grained model for the simulations was done with the MARTINI coarse grain force 
field [56] for biomolecular systems. Combining the ElneDyn elastic network model [57] 
with the coarse grain molecular force field to maintain the secondary and tertiary structure 
of apoA1, we simulated the self-assembly of eHNP-A1 in a 15 x 15 x 15 nm simulation 
box with a periodic boundary and a trajectory of 1000 ns. The initial conditions of the 
simulation involved 2 apoA1 molecules arranged in antiparallel around 160 DMPC lipids 
using the insane method for lipid bilayers. Using the same boundary box size of 15 x 15 x 
15 nm and number of lipids, we initiated 1 μs trajectory eHNP-r4F simulations with 
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varying protein: lipid molecular ratios based on our eHNP-A1 simulations and on past 
simulations using the apoA1-mimetic peptides 18A and 4F [80]. To examine the 
aggregation of multiple eHNP-r4F particles, we used the initial conditions of a 30 x 30 x 
30 nm simulation box and a protein: lipid molecular ratio of 1:16 for a trajectory of 3.5 μs.  
 
3.4.2 eHNP synthesis and characterization 
The synthesis conditions used for all NPs were with a Reynolds number of 50, where the 
flow ratio between the side streams and the center stream was 5.5:1 respectively. The NP 
precursor solutions included a lipid solution that was composed of DMPC with a 
concentration of 2.75 mg/mL in 200 proof ethanol, and a protein solution that had either 
apoA1 or r4F with a concentration of 0.2 mg/mL in PBS (1X, pH 7.4). Syringe pumps from 
Harvard Apparatus (Holliston, MA) were used to pump the solutions into the device, from 
which the mixed solution was collected and then triple washed with PBS using a 10,000 
M.W. (30,000 M.W. when incorporating DOX or fluorescent labels) centrifugal filter from 
EMD Millipore Corporation (Darmstadt, Germany) at a speed of 3900 rpm for 20 minutes. 
The size distribution of the final washed sample was measured with a Zetasizer Nano ZS 
from Malvern Instruments (Worcestershire, United Kingdom). Protein and lipid precursor 
compositions between eHNP-A1 and eHNP-r4F were tuned to achieve an average size of 










CHAPTER 4. PREDICTION OF PARAOXONASE-1 BINDING 
STRUCTURE AND MECHANISM AGAINST EHNP-A1 
4.1 Background 
4.1.1 Paraoxonase-1 as HDL-associated proteins 
As it has been explained that HDL components are dynamically modified during complex 
biological processes, inducing a heterogeneous feature of HDL and causing altered 
endothelial effects of HDL. For example, paraoxonase-1 (PON1), one of enzymes of HDL, 
contributes to the atheroprotective function of HDL [28, 81, 82], whereas HDL-bound 
serum amyloid A (SAA) becomes pro-inflammatory [32]. Due to the overwhelming 
number of HDL components, however, the mechanisms of the altered effects remain poorly 
understood [36, 37]. 
 
4.1.2 Roles of PON1 with HDL 
As mentioned, PON1 is a major anti-atherogenic related protein with HDL. Several studies 
have shown protective roles against atherosclerosis both in vitro and in vivo. In terms that 
lipid oxidation is major cause of atherosclerosis, there have been many experimental 
evidences that PON1 prevents LDL oxidation in vitro [61, 83, 84], as well as PON1 level 
has inverse association with the risk for CVD [85]. 
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4.1.3 PON1 structure 
PON1 has 354 amino acids and the weight of PON1 is 43kDa. It has two major alpha 
helices (H1 and H2), which are known as anchoring site when interacting with HDL, 
because of its hydrophobicity [86]. Although the structure of PON1 has been extensively 
studied, it is still unclear about how the PON1 binds to HDL, which is critical to 
demonstrate the function of HDL.  
 
4.1.4 Expected PON1 binding structure to HDL 
Knowing binding structure is critical to demonstrate potential binding mechanism, which 
allow us to expect the function of molecules. Fortunately, PON1 structure is well 
Figure	18.	Paraoxonase-1	structure	for	coarse-grained	model 
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documented to implement MD simulation. Before the implementation of simulations to 
find preferable PON1 binding structure to HDL, I predicted final PON1 binding structure 
based on literature studies. This is an essential step to reduce simulation time significantly 
by setting up proper initial configuration. Theoretically proposed model has demonstrated 
the reason why two major alpha helices of PON1 were involved in interaction with HDL, 
and several studies have shown PON1 and apoA1 interaction (protein-protein interaction). 
Based on this background, I expected PON1 binding structure to HDL that two alpha 
helices of PON1 directed towards the hydrophobic core, and PON1 would be found in the 






4.2.1 Preferable PON1 binding structure to eHNP-A1 
we proved the interaction of PON1 with the aforementioned -A1 model with 1:80 of 
apoA1-to-DMPC ratio, which was the most relevant ratio for our eHNP-A1 from the 
microfluidic synthesis. 6 different CG MD simulations were performed to explore 
preferable binding structure to eHNP-A1. To judge binding stability and binding strength, 
RMSD and interaction energy were calculated, respectively. 
 
4.2.1.1 6 Initial configurations for parametric study 
Prediction of accurate protein binding is still difficult in this field, because energy 
landscape is generally complicated with many local minima. In other words, protein may 
easily interact to particular site of molecule, where the local minima exist. For this reason, 
so many simulations have to be planned to find global minima, statistically. In this work, I 
conducted 6 MD simulations, placing PON1 molecule in 6 different locations against 
eHNP-A1. Besides two major alpha helices of PON1 faced towards the hydrophobic core 
of eHNP-A1.     
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4.2.1.2 Hydrophobic interaction of final binding structures 
Figure	 20.	 6	 initial	 configurations	 to	 find	 preferable	 PON1	 binding	
structure	to	eHNP-A1 
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All simulations have run through 1000 ns, which were enough time to say convergence. In 
final structures, each PON1 were located at the outer of apoA1-ring, although detailed 
configurations were different. And the binding was mainly driven by hydrophobic 
interaction (LJ potential dominant). Interestingly, the three configurations (#1, 5, 6) look 
similar in terms that two alpha helices of PON1 faced towards the hydrophobic core of 
eHNP-A1. And those three binding structures are agreed with expected model based on 
Figure	21.	Hydrophobic	binding	mechanism	of	eHNP-A1-PON1 
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theoretical proposal. So, it would be good to analyze binding strength and molecule 
stability to confirm preferable PON1 binding structure to eHNP-A1.  
 
4.2.1.3 Interaction energy analysis between PON1 and eHNP-A1 
Four configurations (#1, 4, 5, 6) yielded relatively high attractive interaction of PON1 to 
eHNP-A1, whereas configuration #2 and 3 exhibited low attraction. In detailed analysis of 
high attractive cases, configuration #1, 5, 6 showed that the location of H1 and H2 was 
obviously headed to the hydrophobic core of nanoparticle, while the PON1 was located 
Figure	22.		Final	binding	structures 
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4.2.1.4 Interaction energy analysis between PON1 and apoA1 
Interestingly, configuration #4, which also showed strong interaction energy, showed that 
PON1 interacted mainly with apoA1, while H1/H2 were not oriented toward the core of 
nanoparticle, implying relatively weak contribution of H1 and H2 to the binding. Besides, 
apoA1 dominant interaction increased degree of freedom of PON1 that gave a chance to 
rise mobility.  
Figure	24.	Interaction	energy	analysis	for	PON1	binding	strength	to	apoA1 
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4.2.1.5 Binding stability of PON1 
As a next, I analyzed the root mean square deviation (RMSD) of PON1 on eHNP-A1 to 
demonstrate the structural stability of the PON1 binding. Although configuration #4 
exhibited high binding attraction, it exhibited the highest RMSD value, meaning the 
structural instability of eHNP-A1-PON1 in this configuration. This result is closely 
connected to the results from the interaction energy between PON1 and apoA1 in eHNP-
Figure	 25.	 RMSD	 comparison	 for	 structural	
stability 
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A1. Interaction energy analysis showed dominant interaction strength between PON1 and 
apoA1 in #4, and this increased degree of freedom of PON1 that led to lose binding 
stability.   
 
4.2.1.6 Preferable PON1 binding structure to eHNP-A1 
Therefore, we suggest a preferable binding structure of eHNP-A1-PON1 based on our 
computational analyses; PON1 is located outer ring of eHNP-A1 near apoA1 with two 
major alpha helices of PON1 directed toward the hydrophobic core of eHNP-A1. This 
preferable binding structure is also agreed with the theoretically proposed model and 




4.2.2 eHNP-A1-PON1 model with experimental correlation 
In the final PON1 binding structure on eHNP-A1 (eHNP-A1-PON1), PON1 was found 
near the outer ring of HDL-A1, where double belted two apoA1s are located. In detail, two 
major alpha helices of PON1 were towards the hydrophobic lipid core of eHNP-A1 by 
anchoring on DMPC, while the other parts of PON1 bound to apoA1, suggesting the 
combinatorial interaction of alpha helices of PON1 with lipid core and protein-protein 
interaction of PON1 and apoA1. The binding of PON1 on HDL-A1 did not alter the original 
dimension formed by DMPC and apoA1, but the marginal location of PON1 contributed 
slight size increase. We then investigated the correlation between modelled eHNP-A1-
PON1 and experimentally synthesized eHNP-A1-PON1. By comparing to the morphology 
and size of eHNP-A1, PON1 in eHNP-A1-PON1 was found on the side of eHNP-A1, 
where apoA1s were located, demonstrating the strong correlation with our simulation 
results.. Enzymatic activity of PON1 in eHNP-A1-PON1 was significantly higher as 
expected, due to PON1 activity stabilization by HDL nanoparticles and apoA1[87-90],  
adding evidences of the successful realization of the binding of PON1 on eHNP-A1 in our 
synthesis approach.  
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4.2.3 Multiple PON1 binding possibility  
Multiple PON1 binding was also observed in both approaches. No one has showed about 
multiple PON1 binding. MD simulation provided the possibilities that HDL could interact 
with more than a single PON1. Although we found out the image of two PON1 binding to 
eHNP-A1 in particular region in a TEM grid, more works are needed to verify and propose 
its significance. Also, the TEM image might be controversial, questioning that how we can 
recognize that the two particles are PON1. Not like computational simulation, one 
Figure	 27.	 Morphology	 comparison	 between	 eHNP-A1	 and	 eHNP-A1-PON1	 with	
computational	 and	 experimental	 approach.	 PON1	 enzyme	 activity.	 ***p	 <	 0.001,	
****p	<	0.0001 
 49 
difficulty in experiment is that there is no way to synthesize 2 PON1 with 1 eHNP-A1 on 
purpose, even though we use 2 to 1 ratio for synthesis.    
Figure	28..	Multiple	PON1	binding	to	discoidal	eHNP-A1 
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4.2.4 PON1 binding to spherical form of eHNP-A1 
HDL particles exist in various forms in the physiological condition, from discoidal to 
spherical shape [6]. Recent studies have showed the enzymatic activity of PON1 varies 
with different HDL subclasses [91-93], therefore, it is critical to understand PON1 binding 
to different compositions and/or shapes of HDL nanoparticles. I further performed PON1 
binding to the two spherical eHNP-A1s, double-belt and trefoil to investigate apoA1 
structure dependent. Interestingly, PON1 successfully bound to the double-belt eHNP-A1, 
but not with the trefoil eHNP-A1, suggesting specific apoA1 configuration is critical for 
the binding of PON1 to eHNP-A1. A series of these results suggests that the conformation 
of apoA1 in functionally active PON1-HDL might be a double-belted form in the 
physiological condition.  
4.3 Conclusion 
CG MD simulations have been performed to explore one of HDL-associated proteins, 
PON1 binding to eHNP-A1. It is important to know the protein binding structure in terms 
Figure	29.	PON1	binding	to	other	forms	and	composition	of	eHNP-A1 
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that we can ultimately predict the function of molecule based on that. 6 different PON1 
orientations have been implemented to prove preferable PON1 binding structure with 
interaction energy analysis and binding stability. Comprehensive analysis supported 
preferable binding structure, and that structure is also agreed with theoretically proposed 
model and past experiments. Even with the experimental correlation, our proposal of PON1 
binding structure to eHNP-A1 was verified. With this computational power, I explored 
PON1 binding to spherical eHNP-A1 with two different apoA1 structure, which were hard 
to control the apoA1 structure in HDL in experiment. The results showed that PON1 
binding depended on apoA1 structure.  
4.4 Discussion 
I have explored the binding between PON1 and eHNP-A1, and suggested PON1 binding 
structure and mechanism to eHNP-A1. Simulation results were closely agreed with 
theoretical model and our experimental results. As there are various other HDL-associated 
proteins, my simulation approach would be good to apply for binding mechanism to HDL. 
And this is critical to predict the function of HDL with HDL-associated proteins, because 
recent studies have shown dysfunctional HDL regarding which enzyme protein interact 
with.        
4.5 Methods 
4.5.1 MD simulation 
 GROMACS 4.5.7 [70] was used as MD simulation software package with MARTINI force 
field [56] in conjunction with ElNeDyn[57]  to maintain secondary and tertiary structure. 
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Double-belt apoA1 structure was obtained from CHARMM-GUI [71, 72]. DMPC 
molecules were used as phospholipid. For 3 simulation cases, 120, 160, and 200 number 
of DMPC bilayer molecules were located inside of double belt apoA1 in 15 x 15 x 15 x nm 
sized simulation box, as an initial configuration. The system was solvated with water 
molecules and neutralized with Na+ counterions. Then, this system was energy minimized 
with steepest descent algorithm for 5000 steps. Next, equilibrium step was performed with 
molecule restraints. Simulation time step, 20 fs was set up, which is proper range in 
MARTINI force field. Total simulation time, 1000 ns was set for all simulations. 
Temperature kept 298K for RT.  
 
4.5.2 Synthesis of eHNP-A1 and eHNP-A1-PON1 
A three-inlet microfluidic device that generates propagating microvertices was used for a 
single-step self-assembly of eHNP-A1 according to the previous report with slight 
modification. In brief, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Polar 
Lipids, AL; 2.75 mg/mL) in absolute ethanol was introduced into the center inlet of the 
microfluidic device at a flow rate of 0.8 mL/min. Apolipoprotein A1 (Millipore Sigma, 
MA; 0.2 mg/mL) in phosphate buffered saline (PBS, pH = 7.4) was introduced into two 
outer inlets at a flow rate of 2.2 mL/min. Each of DMPC and apoA1 solution was 
homogenously injected using a programmable syringe pump (Harvard Apparatus, MA) at 
the desired flow rates. After running the syringe pump, the mixture solution was collected 
from outlet, followed by transferring the solution to centrifugal membrane filter (EMD 
Millipore, Germany) with a molecular weight cut off (MWCO) of 50,000, and purified 5 
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times in PBS at a speed of 3900 rpm for 30 min. Synthesized eHNP-A1 was stored at 4oC 
for further modification.  
For PON-1 incorporation, medium of eHNP-A1 was replaced from PBS to Hank’s 
Balanced Salt Solution (HBSS, pH = 7.4). After quantification of apoA1 in eHNP-A1 using 
BCA assay according to the manufacturer’s protocol, 0.5 equivalent PON1 to apoA1 was 
added to eHNP-A1, and incubated for 2 h at 37 oC with gentle pipetting for every 15 min. 
After the incubation, the solution was transferred to centrifugal membrane filter (EMD 
Millipore, Germany) with a MWCO of 50,000, and purified 3 times in HBSS at a speed of 
3900 rpm for 20 min. The purified solution was stored at 4oC. 
4.5.3 Characterization of eHNP-A1 and eHNP-A1-PON1 
Hydrodynamic volume of eHNP-A1 and eHNP-A1-PON1 were obtained by a Zetasizer 
Nano (Malvern Instrument, Malvern, UK). The amount of PON1 in eHNP-A1-PON1 was 
quantified by running sodium dodecyl sulfate poly(acrylamide) gel electrophoresis (SDS-
PAGE, separating phase of 12% acrylamide), and calculating the band intensity using 
imageJ software. PON1 activity of naïve PON1, eHNP-A1-PON1, and corresponding 
amout of eHNP-A1 was analyzed by EnzChek paraoxonase assay kit (Thermo Fisher) 
according to the manufacturer’s protocol. For the monitoring of size and morphology of 
eHNP-A1 and eHNP-A1-PON1, negatively stained samples were observed using a 
transmission electron microscope (TEM; Hitachi 7700, Hitachi, Japan) at 120kV coupled 
with the Digital Micrograph camera and software suite from Gatan. 
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4.6 Supporting information 
4.6.1 eHNP-A1 and eHNP-A1-PON1 comparison in TEM and DLS 
 
Figure	S	2.	Figure	S1.	Morphology	of	 eHNP-A1	and	eHNP-A1-PON1	 from	experiment.	 (a)	
TEM	 image	 of	 eHNP-A1	 (b)	 DLS	 size	 distribution	 of	 eHNP-A1	 in	 number	 (c)	 DLS	 size	
distribution	 of	 eHNP-A1	 in	 intensity	 (d)	 TEM	 image	 of	 eHNP-A1-PON1	 (e)	 DLS	 size	
distribution	 of	 eHNP-A1-PON1	 in	 number	 (f)	DLS	 size	 distribution	 of	 eHNP-A1-PON1	 in	
intensity	
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CHAPTER 5. CONCLUSION 
HDL has long been studies because of its importance in term of inverse association with 
cardiovascular disease, which is top cause of death in US. For this reason, HDL research 
has been comprehensively documented regarding the structure, function, and HDL 
associated protein enzymes. HDL is a multifunctional nanoparticle, as well as it has various 
shapes and compositions. However, the heterogeneous popularity is still a major hurdle to 
investigate the characteristics of HDL nanoparticle. 
Despite of heterogeneity of HDL, the various approaches to HDL research has also been 
suggested because of the importance of HDL. Reconstituted HDL has been developed with 
major components of HDL as simplified form. And microfluidics technology has been 
applied to synthesize homogeneous nanoparticles with high reproducibility. Further, MD 
simulation has been introduced to analyze the structure and to predict the function and 
molecule binding mechanism, along with the development of computer performance. 
Although HDL structure, function, and the relation to HDL-associated proteins have been 
well documented with given approaches, other unexpected function of HDL has been 
shown in recent clinical studies. In other words, HDL cannot be anymore called “Good 
cholesterol”. It has been known that dysfunctional HDL is related to HDL-associated 
proteins. For example, PON1 functionalizes HDL as anti-inflammatory and antioxidative 
roles. On the other hand, SAA induces pro-inflammatory.  
In my work, I applied MD simulation approach to explore HDL-mimetic nanoparticles. 
MD simulation is one approach that enables molar level analysis that helps to understand 
nanoparticle structure, function and molecule binding mechanism. With this approach, I 
was able to investigate HDL-mimetic nanostructures, which has yet to be explored. After 
validate MD simulation setup with experimental correlations, I have shown that structural 
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deformation of discoidal eHNP-A1 suggesting maximum loading capacity. Further, 
structural analysis revealed why apoA1-mimetic peptide-based nanostructure has less 
stability than apoA1-based nanoparticle with the advantage of MD simulation. Finally, I 
proposed preferable PON1 binding structure to eHNP-A1, which is important to predict 
HDL function and binding mechanism.  
There are still many things to do with MD simulation regarding HDL research, such as the 
structural analysis with different compositions and shapes, and the binding structure 
prediction with other HDL-associated proteins to propose. My approach would definitely 
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